Burr D B
Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 46202-5120, USA.
J Musculoskelet Neuronal Interact. 2002 Mar;2(3):201-4.
The strength of bone is related to its mass and geometry, but also to the physical properties of the tissue itself. Bone tissue is composed primarily of collagen and mineral, each of which changes with age, and each of which can be affected by pharmaceutical treatments designed to prevent or reverse the loss of bone. With age, there is a decrease in collagen content, which is associated with an increased mean tissue mineralization, but there is no difference in cross-link levels compared to younger adult bone. In osteoporosis, however, there is a decrease in the reducible collagen cross-links without an alteration in collagen concentration; this would tend to increase bone fragility. In older people, the mean tissue age (MTA) increases, causing the tissue to become more highly mineralized. The increased bone turnover following menopause may reduce global MTA, and would reduce overall tissue mineralization. Bone strength and toughness are positively correlated to bone mineral content, but when bone tissue becomes too highly mineralized, it tends to become brittle. This reduces its toughness, and makes it more prone to fracture from repeated loads and accumulated microcracking. Most approved pharmaceutical treatments for osteoporosis suppress bone turnover, increasing MTA and mineralization of the tissue. This might have either or both of two effects. It could increase bone volume from refilling of the remodeling space, reducing the risk for fracture. Alternatively, the increased MTA could increase the propensity to develop microcracks, and reduce the toughness of bone, making it more likely to fracture. There may also be changes in the morphology of the mineral crystals that could affect the homogeneity of the tissue and impact mechanical properties. These changes might have large positive or negative effects on fracture incidence, and could contribute to the paradox that both large and small increases in density have about the same effect on fracture risk. Bone mineral density measured by DXA does not discriminate between density differences caused by volume changes, and those caused by changes in mineralization. As such, it does not entirely reflect material property changes in aging or osteoporotic bone that contribute to bone's risk for fracture.
骨骼的强度与其质量和几何形状有关,也与组织本身的物理特性有关。骨组织主要由胶原蛋白和矿物质组成,它们都会随着年龄的增长而发生变化,并且都可能受到旨在预防或逆转骨质流失的药物治疗的影响。随着年龄的增长,胶原蛋白含量会减少,这与平均组织矿化增加有关,但与年轻成人骨骼相比,交联水平没有差异。然而,在骨质疏松症中,可还原的胶原蛋白交联减少,而胶原蛋白浓度没有改变;这往往会增加骨骼的脆性。在老年人中,平均组织年龄(MTA)增加,导致组织矿化程度更高。绝经后骨转换增加可能会降低整体MTA,并会减少整体组织矿化。骨强度和韧性与骨矿物质含量呈正相关,但当骨组织矿化程度过高时,它往往会变脆。这会降低其韧性,并使其更容易因反复负荷和累积微裂纹而骨折。大多数已获批的骨质疏松症药物治疗会抑制骨转换,增加MTA并促进组织矿化。这可能会产生以下一种或两种效果。它可以通过重塑空间的重新填充来增加骨量,降低骨折风险。或者,增加的MTA可能会增加产生微裂纹的倾向,并降低骨骼的韧性,使其更有可能骨折。矿物晶体的形态也可能发生变化,这可能会影响组织的均匀性并影响力学性能。这些变化可能对骨折发生率产生很大的正面或负面影响,并可能导致这样一种矛盾现象,即密度的大幅增加和小幅增加对骨折风险的影响大致相同。通过双能X线吸收法(DXA)测量的骨矿物质密度无法区分由体积变化引起的密度差异和由矿化变化引起的密度差异。因此,它不能完全反映衰老或骨质疏松性骨骼中导致骨折风险的材料特性变化。